RxDoctor Payments DataLook up a doctor →

Tirrell Johnson, MD

Hematology & Oncology · Orlando, FLNPI 1518042415

Payments from drug & device makers

$2,614,513in general payments, 2019–2025

Across 534 payments — averaging $4896.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$613K
  • Boehringer Ingelheim$527K
  • Janssen Research & Development, LLC$375K
  • Regeneron$260K
  • Daiichi Sankyo Inc.$235K
  • Merck$230K
  • plus $374K from 17 others

What the payments were for

  • Food & beverage$91499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,614,513 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$81,779
Medicare patients
277
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate91$1,573,267
TafinlarDabrafenib Mesylate28$317,142
MekinistTrametinib Dimethyl Sulfoxide20$315,378
OdomzoSonidegib Phosphate24$305,361
KrazatiAdagrasib11$241,987
MektoviBinimetinib15$232,970
AlecensaAlectinib Hcl12$221,177
BraftoviEncorafenib13$166,690
GilotrifAfatinib Dimaleate13$149,204
TabrectaCapmatinib Hydrochloride12$130,794
LumakrasSotorasib13$128,547
Everolimus13$120,300
CometriqCabozantinib S-Malate13$103,876
Sunitinib Malate19$69,589
EliquisApixaban38$25,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$36,793$1,573,26791 claims
Genentech USA, Inc.Alecensa$101$221,17712 claims
Boehringer IngelheimGilotrif$526,508$149,20413 claims
PfizerEliquis$60,582$25,70338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →